Viking Therapeutics (VKTX) Peer Comparison

$34.44

$0.46 (1.35%)

As on 04-Sep-2026 13:35EDT

Market cap

$3,752 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

9.7

Div. Yield

0 %

Edit

	Viking Therapeutics (VKTX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Market cap ($ Mln)	3,752	16,765	16,261	13,492	12,332
Revenue ($ Mln)	--	2,782	1,054	2,436	1,284
Net Profit ($ Mln)	-534.80	491.50	755.85	860.62	-325.10
Net Margin (%)	--	17.67	71.69	35.33	-25.32
RoE (%)	-102.12	110.09	--	42.98	-57.72
Price to Earnings	--	35.25	19.00	17.40	--
Price-To-Book	9.67	39.29	9.76	7.42	23.98

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Viking Therapeutics (VKTX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Operating Revenue	0.00	2,782.29	1,054.37	2,435.92	1,283.94
Cost of Revenue	0.21	1,982.07	103.47	85.67	109.42
Gross Profit	-0.43	760.62	588.53	2,236.43	902.26
Operating Expenses	560.02	216.81	841.45	1,378.74	1,497.13
Operating Profit (EBIT)	-560.02	583.40	109.45	971.51	-322.62
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-534.80	598.92	101.11	1,035.47	-325.10
Provision for Tax	0.00	107.42	-654.74	174.84	0.00
Profit after Tax (Net Income)	-534.80	491.50	755.85	860.62	-325.10
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Viking Therapeutics (VKTX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Shareholder's Funds	408.32	433.86	1,435.90	1,843.76	523.72
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	3.93	187.89	384.48	288.55	346.72
Current Liabilities	109.66	1,435.43	464.70	361.93	374.20
Total Liabilities	715.73	1,975.47	1,302.02	2,844.42	1,259.59

Assets ($ Mln)

	Viking Therapeutics (VKTX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Non-Current Assets	4.33	1,006.90	895.24	1,243.41	45.47
Current Assets	517.56	1,050.29	1,389.84	1,250.82	1,199.18
Total Assets	715.73	1,975.47	1,302.02	2,844.42	1,259.59
Total Debt*	4.09	120.10	449.89	165.93	347.75
Net Current Assets	407.91	-385.14	0.00	888.90	824.98

Cashflow ($ Mln)

	Viking Therapeutics (VKTX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Cash From Operating Activities	-278.69	713.22	51.77	884.27	-189.55
Cash Flow from Investing Activities	341.39	-31.14	-8.15	350.44	32.32
Cash from Financing Activities	76.44	-860.39	34.89	-969.59	255.98
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Viking Therapeutics (VKTX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
ROCE (%)	-47.30	53.56	-30.01	32.82	-31.49
ROE (%)	-102.12	110.09	163.18	42.98	-57.72
ROA (%)	-71.72	15.64	26.53	29.32	-22.97
EBIT Margin (%)	--	21.13	5.73	31.04	-18.97
Net Margin (%)	--	17.67	71.69	35.33	-25.32
Cash Profit Margin (%)	--	0.00	0.00	0.00	0.00

Growth Ratios

	Viking Therapeutics (VKTX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Revenue Growth (%)	--	24.67	114.85	9.23	149.04
EBIT Growth (%)	-119.57	18.70	136.39	-3.99	9.16
Net Profit Growth (%)	-211.75	17.50	378.76	42.89	-15.32
EPS Growth (%)	-204.00	26.84	353.27	50.42	-0.64
Book Value Growth (%)	-50.34	164.02	816.12	-0.70	-42.66

Valuation Ratios

	Viking Therapeutics (VKTX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Price / Earnings	-11.15	36.06	-59.76	15.79	-45.32
Price / Book Value	6.28	35.44	-80.42	5.72	21.68
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-9.20	28.08	-121.54	12.44	-47.02
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Viking Therapeutics (VKTX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Debt to Equity	0.00	0.00	0.00	0.00	0.65
Short term debt to equity ratio	0.00	0.00	0.05	0.00	0.00
Current Ratio	4.72	0.73	2.99	3.46	3.20
Quick Ratio	4.72	0.73	2.32	3.38	2.94
Interest Coverage	-66,848.50	--	1.62	--	-19.80

Operating Efficiency Ratios

	Viking Therapeutics (VKTX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Debtors to sales (%)	--	15.88	21.25	13.74	14.98
Asset Turnover	0.00	0.89	0.37	0.83	0.91
Receivable days	--	50.42	85.52	43.48	35.88
Inventory Days	--	--	1,056.70	96.17	354.23
Payable days	26,721.72	6.26	331.01	147.97	300.79
Cash Conversion Cycle	--	--	811.21	-8.32	89.33

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly